Oslo  (Norway), 4 September 2019 - Exercise of employee share options, mandatory
notification  of  trade  and  resolution  to  increase  the share capital in PCI
Biotech Holding ASA (the "Company").

1.   Options exercised and mandatory notification of trade
Primary  insider Ronny Skuggedal (CFO) has on 4 September 2019, as a participant
in  the Company's share option program, exercised a total number of 40,000 share
options  at a  strike price  of NOK  8.63. The share  options were granted to Mr
Skuggedal in October 2013 and now about to expire unless exercised.

Subsequent to the exercise he has sold 25,300 shares in the market at an average
price  of NOK 27.08 per share in order to finance the cash and tax impact of the
transaction. After the transaction Mr. Skuggedal hold 43,000 shares and 116,000
share options in the Company.

This  announcement also represents  a mandatory notification  of trade, which is
submitted by the Company on behalf of the primary insiders.

2.   Resolution to increase the share capital
Following the exercise of share options on 4 September 2019, the Company's Board
of  Directors,  pursuant  to  an  authorisation  granted by the Company's Annual
General  Meeting on  29 May 2019, have  decided to  increase the Company's share
capital  with NOK 120,000 by issuing 40,000 new  shares, each share of par value
NOK 3.00. Subsequent to the transaction, the Company's share capital will be NOK
111,797,670 divided  into 37,265,890 shares,  each with  a nominal  value of NOK
3.00 and  each giving  one vote  at the  Company's general  meeting. The capital
increase will result in gross proceeds of NOK 345 200.

Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section
4-12 and 5-12 of the Norwegian Securities Trading Act.